Back
Science

Study Indicates Menstrual Blood HPV Testing Comparable to Traditional Cervical Cancer Screening

Generated on: Last updated: 3 sources
View source

Revolutionary HPV Testing: Menstrual Blood Offers New Hope for Cervical Cancer Screening

A new study published in The BMJ suggests that human papillomavirus (HPV) testing using self-collected menstrual blood, gathered via sanitary pads, demonstrates diagnostic accuracy comparable to clinician-collected samples for detecting high-grade cervical lesions. Researchers indicate this non-invasive method could offer a scalable, patient-friendly alternative, potentially reducing barriers to cervical cancer screening globally.

This innovative approach could offer a scalable, patient-friendly alternative, potentially reducing barriers to cervical cancer screening globally.

Understanding Cervical Cancer Screening

Cervical cancer remains a significant global health concern, with approximately 661,000 new cases and 348,000 deaths reported annually. A staggering 85% of these cases occur in developing countries. The disease is primarily caused by chronic infection with high-risk HPV strains, but it is largely preventable through timely HPV screening and treatment of precancerous lesions, known as cervical intraepithelial neoplasia (CIN) grade 2 or higher (CIN2+).

Current standard cervical screening methods typically involve a clinician collecting a cervical sample. These methods often face limitations, including resource constraints, low awareness, cultural and religious factors, and discomfort or stigma. Such barriers frequently lead many eligible individuals not to participate in life-saving screenings. To address these challenges, self-sampling methods, such as vaginal swabs, tampons, and cervicovaginal brushes, have been explored as alternatives.

The Groundbreaking Study

The community-based trial involved 3,068 women, aged 20 to 54, with regular menstrual cycles, enrolled from seven communities in Hubei Province, China, between 2021 and 2025. Participants provided three types of samples for analysis:

  • Menstrual blood collected using a minipad, a prototype designed for optimal DNA collection.
  • A clinician-collected cervical sample for HPV testing.
  • A ThinPrep cytology sample for cell abnormality assessment.

Women whose samples tested HPV-positive or showed suspicious cytology results were referred for colposcopy and biopsy. Those testing negative on both HPV tests with normal cytology were advised annual follow-up. HPV testing specifically targeted 14 high-risk genotypes, which are considered markers for CIN2+ or CIN3+ risk.

Among the clinician-collected samples, 11.0% tested positive for HPV, and 13.3% of participants were referred for colposcopy. Diagnoses stemming from these referrals included 52 cases of CIN1, 24 cases of CIN2, 13 cases of CIN3, and one case of invasive cervical cancer.

Key Findings: Diagnostic Accuracy

The study rigorously assessed the diagnostic accuracy of the menstrual blood samples when compared to clinician-collected samples:

  • Sensitivity for CIN2+: Minipad-collected menstrual blood demonstrated a sensitivity of 94.7% for detecting CIN2+, which was comparable to the 92.1% sensitivity of clinician-collected samples. Both methods showed significantly higher sensitivity than cytology, which was 78.9%.
  • Specificity for CIN2+: Minipad-collected samples had a specificity of 89.1%, while clinician-collected samples had 90.0%. Both were lower than the specificity of cytology, which was 96.2%.
  • Negative Predictive Value (NPV): The likelihood that an individual with a negative test result truly did not have CIN2+ was an impressive 99.9% for both minipad and clinician-collected HPV tests.
  • Positive Predictive Value (PPV): The PPV was 9.9% for minipad samples and 10.4% for clinician-collected samples.
  • CIN3+ Detection: For detecting CIN3+, minipad-based testing showed a sensitivity of 92.9%, compared to 85.7% for clinician-collected samples and cytology.
  • Screening Efficiency: The number of colposcopies required per CIN2+ diagnosis was comparable, with 10.1 for minipad samples and 9.6 for clinician-collected samples. A similar pattern was observed for CIN3+ detection.
  • HPV Genotype Concordance: The study reported a complete HPV genotype concordance of 96.2% and a total concordance of 97.7% between the two HPV sample types. HPV 16 and 18 were found in 37.5% of minipad-based positive tests and 31.8% of clinician-collected samples.

Researchers reported that the minipad HPV test met predefined non-inferiority criteria when compared with clinician sampling. The study protocol also demonstrated a high negative predictive value, suggesting a low rate of missed high-grade lesions. Integration with a mobile application was noted to facilitate patient communication, test results, and health education.

Implications and Future Outlook

The study authors concluded that these findings strongly support integrating menstrual blood-based HPV testing into national cervical cancer screening guidelines. They present it as a potentially scalable, patient-friendly, and non-invasive approach for large-scale screening and expanding global access. Researchers noted that self-sampling methods offer significant advantages such as privacy, comfort, convenience, and cost-effectiveness.

Expert Perspectives

Experts not involved in the study also weighed in:

  • Sophie Brooks, health information manager at Cancer Research UK, described the research as "encouraging" for making cervical screening more accessible and noted menstrual blood HPV testing as an "interesting, non-invasive approach."
  • Xavier Bosch, an emeritus researcher at the Catalan Institute of Oncology, characterized the work as "very pioneering."
  • Athena Lamnisos, chief executive of the Eve Appeal, a gynaecological cancer charity, welcomed the potential for "new, more acceptable and potentially gentler ways" to offer life-saving tests.

Considerations and Next Steps

However, experts also emphasized that the research is in its early stages and requires larger, more diverse trials to fully understand its effectiveness across various populations and how it might integrate into existing screening pathways. It was also noted that this method may not be suitable for all individuals, such as menopausal women.

Researchers acknowledged a potential limitation: the broader sampling area of menstrual blood might detect HPV infections beyond the cervix, potentially increasing false positives and the need for additional triage strategies in future programs. Further research is needed to compare menstrual blood testing with other validated self-samples and to conduct longitudinal studies to assess real-world detection rates, cost-effectiveness, and deployment obstacles.